期刊文献+

喷雾干燥法制备脊髓灰质炎微球减毒活疫苗 被引量:2

Preparation of Live Attenuated Poliomyelitis Vaccine Microspheres by Spray Drying
原文传递
导出
摘要 目的采用喷雾干燥法制备脊髓灰质炎微球减毒活疫苗。方法以正交试验法筛选最佳保护剂配方及最佳工艺条件,通过样品的得率、含水量、病毒滴度、微球形态、粒径大小分布和热力学性质等特性评价疫苗的稳定性。结果最佳喷雾干燥工艺为:入口风温180℃,入口风压3.9m/s,进样速度2.5ml/min,保护剂配方1.5%海藻糖+0.2%人血白蛋白(HSA)+0.2%聚乙烯吡咯烷酮(PVP)(w/v)。微球形态完整,分散性好,平均粒径为10.9μm,得率为54.25%,干粉疫苗37℃放置1周和25℃保存6个月,病毒的滴度下降不超过0.5lgCCID50/ml。结论喷雾干燥法制备的脊髓灰质炎微球减毒活疫苗稳定性好,工艺简便,易于工业化生产。 Objective To prepare live attenuated poliomyelitis vaccine mirospheres by spray drying. Methods The optimal formula of protective agent and condition for preparation were screened by orthogonal test. The stability of vaccine was evaluated with yield,moisture content,virus titer,morphology of microspheres,size distribution and thermodynamic properties. Results The optimal inlet temperature,dying air speed and pump speed for spray drying were 180℃,3. 9 m / s and 2. 5 ml / min respectively. The optimal formula of protective agent was as follows:1. 5% trehalose,0. 2% human serum albumin (HSA) and 0. 2% polyvinylpyrrollidone (PVP). The prepared microspheres showed intact shapes and good dispersity,and their mean size and yield were 10. 9 μm and 54. 25% respectively. After storage at 37℃ for 1 week and at 25℃ for 6 months,both the decreases of virus titers of prepared vaccine mirospheres were not more than 0. 5 lgCCID50 / ml. Conclusion The live attenuated poliomyelitis vaccine mirospheres prepared by spray drying showed good stability. The preparation procedure was simple and suitable for industrial production.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第4期366-370,共5页 Chinese Journal of Biologicals
关键词 脊髓灰质炎 减毒活疫苗 微球 喷雾干燥 Poliomyelitis Live attenuated vaccine Mirospheres Spray drying
  • 相关文献

参考文献10

  • 1Bey R, Simonson R, Garcon N. Formulation of vaccines//Hardee GE, Baggot JD. Development and formulation of veterinary dosage forms. 2nd ed. New York: Informa Healthcare, 1998: 283-303.
  • 2Van Campen L, Venthoye G. Inhalation, dry powder//Swarbrick J, Boylan JC. Encyclopedia of pharmaceutical technology. 2nd ed. New York: Informa Health care, 2002: 1529-1544.
  • 3Corbanie EA, Remon JP, Van Reeth K, et al. Spray drying of an attenuated live Newcastle disease vaccine virus intended for respira- tory mass vaccination of poultry. Vaccine, 2007, 25 (49):8306- 8317.
  • 4Burnett DJ, Thiehnann F, Booth J. Determining the critical relative humidity for moisture-induced phase transitions. Int J Pharm, 2004, 287(1-2): 123-133.
  • 5Clas SD, Dalton CR, Hancock BC. Calorimetry in pharmaceutical research and development//Swarbrick J, Boylan JC. Encyclopedia of pharmaceutical technology. 2nd ed. New York: Informa Health care, 2002: 289-301.
  • 6Carcaboso AM, Hernandez RM, Igartua M, et al. Potent, long lasting systemic antibody levels and mixed Th/Th2 immune re-sponse after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine, 2004, 22 (11-12): 1423-1432.
  • 7Cordone L, Cottone G, Giuffrida S, et al. Internal dynamics and protein-matrix coupling in trehalose-coated proteins. Biochim Biophys Acta, 2005, 1749(2): 252-281.
  • 8Crowe JH, Oliver AE, Hoekstra FA, et al. Stabilization of dry membranes by mixtures of hydroxyethyl starch and glucose: the role of vitrification. Cryobiology, 1997, 35( 1 ): 20-30.
  • 9Hawe A, Friess W. Physico-chemical lyophilization behavior of mannitol, human serum albumin formulations. Eur J Pharm Sci, 2006, 28(3): 224-232.
  • 10Hancock BC, Shamblin SL, Zografi G. Molecularmobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res, 1995, 12(6): 799-806.

同被引文献27

  • 1蹇小婷,王莉.肺吸入给药剂型的研究进展[J].西北药学杂志,2005,20(4):185-186. 被引量:7
  • 2钱伯初,史红,郑晓亮.吸入气雾剂治疗糖尿病和疫苗接种研究若干进展[J].浙江实用医学,2006,11(6):433-436. 被引量:1
  • 3李志义,赵顺轩,蒋静智,刘学武,孟庭宇.超临界辅助雾化法制备红霉素超细微粒[J].高校化学工程学报,2007,21(1):43-47. 被引量:13
  • 4李桂芹.海藻糖的生物学功能及其应用[J].安徽农业科学,2007,35(24):7724-7725. 被引量:14
  • 5AMORIJ J P, KERSTEN G F, SALUJ A V, et al. Towards Tailored Vaccine Delivery.. Needs, Challenges and Perspectives [J]. J Control Release,2011,161(2):363-376.
  • 6LICALSI C,CHRISTENSEN T, BENNETT iV, et al. Dry Powder Inhalation as a Potential Delivery Method for Vaccines [J]. Vaccine, 1999,17(13/14) .. 1796-1803.
  • 7LICALSI C, MANIACI M J ,CHRISTENSEN T, et al. A Powder Formulation of Measles Vaccine for Aerosol Delivery [J]. Vaccine,2001,19(17/18/19) :2629-2636.
  • 8HUANG J ,GARMISE RJ ,CROWDER T M,et al. A Novel Dry Powder Influenza Vaccine and Intranasal Delivery Yechn- ology: Induction of Systemic and Mucosal Immune Responses in Rats [J]. Vaccine, 2004,23 (6) :794-801.
  • 9K ISICH K O, H IGGINS M P, PARK I, et al. Dry Powder Measles Vaccine Particle Deposition, Virus Replication, and Im- mune Response in Cotton Rats Following Inhalation [J]. Vaccine,2011,29(5) 905-912.
  • 10AMORIJ J P,SALUJA V,PETERSEN A H,et al. Pulmonary Delivery of an Inulin-stabilized Influenza Subunit Vaccine Prepared by Spray-freeze Drying Induces Systemic, Mucosal Humoral as Well as Cell-mediated Immune Responses in BALB/e Mice I-iT. Vaccine,2007,25(52) :8707-8717.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部